ADVM - Adverum Biotechnologies Inc. - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

45.63M

Cash

141.5M

Avg Qtr Burn

-23.99M

Short % of Float

1.66%

Insider Ownership

3.65%

Institutional Own.

67.09%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ixoberogene soroparvovec (Ixo-vec) (ADVM-022) (AAV.7m8-aflibercept) Details Wet age-related macular degeneration , Age-related macular degeneration, Eye disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ADVM-022 (AAV.7m8 Afiblercept) Details Diabetes, Eye disease , Diabetic macular edema	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.